Makes treatments for Duchenne muscular dystrophy, including the gene therapy Elevidys.
$17.10close as of 2026-10-16
-26.7% over 1Y · 43.5 points behind the S&P 500
SRPTS&P 500 (SPY), rebased to SRPT's first close
“Can PMO revenues and lower expenses sustain operating profitability while ELEVIDYS remains limited to ambulatory patients?”
Editorial note · updated 2026-10-08
The TenQ Radar
Sarepta Therapeutics in 36 checks
Sarepta Therapeutics on the TenQ Radar: value, growth, quality, health, shareholder returns and trend. The fuller the shape, the stronger the company. Behind each axis are six pass-or-fail checks from its filings, spelled out in the chapters below. Point at an axis to see them.
The business itself is the question here: 12 of 36 checks passed.
The Sarepta Therapeutics story
What drives Sarepta Therapeutics, what its price assumes and what could change the story, written from its own filings.
PMOs anchor revenue. In the quarter to June 2026, PMO products generated $230.6 million of Sarepta's $328.7 million in net product revenues, while ELEVIDYS contributed $98.1 million.
Cost reductions matter. Sarepta achieved $13.3 million in GAAP operating income in the quarter to June 2026 as restructuring reduced research, manufacturing and personnel expenses.
Approval questions remain. FDA acceptance of the AMONDYS 45 and VYONDYS 53 applications advances their review for traditional approval, but does not resolve the uncertainty following ESSENCE's missed primary endpoint.
Q2 '26 · quarter to 30 June 2026 · reported 5 August 2026 · Earnings release ↗
Revenue$401M-34%vs 2025-45%vs Q1
Earnings-$5M-$202Mvs 2025-$336Mvs Q1
What the release says
Highlights
Sarepta Therapeutics reported Q2 2026 net product revenues of $328.7 million, with $230.6 million from PMO products and $98.1 million from ELEVIDYS.
The company achieved both GAAP and non-GAAP operating profitability for the quarter, with GAAP operating income of $13.3 million and non-GAAP operating income of $86.5 million.
A $39.0 million litigation contingency charge was recorded in Q2 2026 related to the potential resolution of certain patent litigations.
Sarepta ended the quarter with approximately $945.0 million in cash, cash equivalents, restricted cash, and investments, an increase of about $197.0 million during the quarter.
What management expects
Sarepta narrowed its 2026 total net product revenue guidance to $1.2-$1.3 billion, consistent with prior expectations toward the lower end of the previous $1.2-$1.4 billion range.
The company also narrowed its combined non-GAAP R&D and SG&A expense guidance for 2026 from $800.0-$900.0 million to $800.0-$850.0 million.
Key risks
New New U.S. government actions in 2026, including most-favored-nation pricing arrangements, tariffs on imported patented pharmaceuticals, and increased transparency on drug pricing, could significantly decrease available coverage and the prices Sarepta can establish for its products.
New Geopolitical challenges, such as the conflicts in Russia, Ukraine, the Middle East, and Venezuela, may disrupt distribution and revenue from Sarepta's products in affected regions, potentially impacting the company's financial condition and growth prospects.
The commercial success of Sarepta's products depends on factors such as effective sales and marketing, consistent manufacturing, adequate reimbursement, and the ability to meet FDA post-marketing requirements, including confirmatory trials for products approved under accelerated approval.
Recent safety events, including patient deaths associated with ELEVIDYS and other gene therapy candidates, have led to label changes and may impact market adoption, regulatory status, and payer coverage for these products.
Sarepta faces significant uncertainty regarding reimbursement policies and pricing pressures, including potential government reforms, which could limit coverage, reduce prices, or impose unfavorable payment models for its products.
The company is exposed to risks from regulatory changes, including new healthcare reforms, evolving FDA requirements, and international regulatory hurdles, which could delay or prevent product approvals, impact exclusivity, or require costly compliance.
AI summary of the company's filings, every number checked against them · 8 October 2026 · Sources: earnings release, 10-K, 10-Q
Earnings alerts
An email when Sarepta Therapeutics reports, with its results and highlights. Free with a watchlist account.
I
Value
●●●●●●4/6
Fairly priced on some measures, rich on others, its sales multiple below its own long-run norm (judged on sales, as it is not yet profitable).
-no history
0.9xown 9-year median 9.6x
4.5%cash earned per $ of price
-whole-business multiple
Valuation history
Is SRPT's P/E, P/S or P/B high or low against its own past?
Year
P/E
P/S
P/B
2024
58.6983
7.2599
9.0383
2026
-
0.9148
1.1822
◌ 2026 = at the latest close (2026-10-16), over the trailing twelve months; earlier years are annual averages · the last point is at the latest close (2026-10-16); earlier quarters use that quarter's average price over the trailing twelve months to it
→At 0.9x sales, the market is paying 90% less than SRPT's own 9-year median of 9.6x. Pessimism is priced in - the question is whether it is deserved.
What this measures
What the market has paid for each dollar of earnings, sales or book value, every year, with today's multiple as the last point and the median drawn across.
What good looks like. There is no good level. What matters is the distance from the company's own history, and whether the business has changed enough to justify it.
If it rises or falls. A multiple above its own median means the market expects more than it used to, so more has to go right. Below the median means the opposite, and the question is whether the pessimism is deserved. A multiple can also fall because earnings rose, which is the good way.
Free cash flow yield
What is SRPT's free cash flow yield at today's price?
Period
FCF yield
2017
-0.106
2018
-0.0641
2019
-0.0599
2020
0.0024
2021
-0.0718
2022
-0.0443
2023
-0.0535
2024
-0.0248
2025
-0.067
2026
0.0453
◌ 2026 = at the latest close (2026-10-16), over the trailing twelve months; earlier years are annual averages · the last point is at the latest close (2026-10-16); earlier quarters use that quarter's average price over the trailing twelve months to it
→Every dollar of market value currently buys 4.5% of annual free cash flow, less than its 9-year median of -6.0% - you are paying up for the same cash.
What this measures
Free cash flow divided by market value: the cash the business generates for every dollar you pay for it. The inverse of a price-to-cash multiple.
What good looks like. A yield at or above the company's own history, and one that compares well with what cash is worth elsewhere.
If it rises or falls. The yield rises when cash grows or the price falls, so a high yield is either a bargain or a warning about the cash continuing. Read it beside the cash conversion chart, which shows whether the cash is holding up.
Value asks what you pay for each dollar of earnings, sales or cash the business produces. A high multiple isn't automatically bad - fast growers earn theirs - but a price far above the company's own history means the market expects a lot to go right. We compare each multiple to the company's own past and to its sector, never to a universal rule.
not profitable: no free cash flow or earnings for the price to rest on
II
Growth
●●●●●●2/6
Growth is weak or inconsistent. The trend, not the story, is the problem.
-20.4%vs the year before
+33.1%compound annual
-net income growth
-compound annual
Revenue history
Is SRPT's revenue growing?
◌ dashed quarter = Q4 derived from the annual filing minus Q1, Q2 and Q3 (the SEC never receives a Q4 report)
Period
Revenue ($)
Q4 2016
5.4M
Q1 2017
16.3M
Q2 2017
35.0M
Q3 2017
46.0M
Q4 2017
57.3M
Q1 2018
64.6M
Q2 2018
73.5M
Q3 2018
78.5M
Q4 2018
84.4M
Q1 2019
87.0M
Q2 2019
94.7M
Q3 2019
99.0M
Q4 2019
100.1M
Q1 2020
113.7M
Q2 2020
137.4M
Q3 2020
143.9M
Q4 2020
145.1M
Q1 2021
146.9M
Q2 2021
164.1M
Q3 2021
189.4M
Q4 2021
201.5M
Q1 2022
210.8M
Q2 2022
233.5M
Q3 2022
230.3M
Q4 2022
258.4M
Q1 2023
253.5M
Q2 2023
261.2M
Q3 2023
331.8M
Q4 2023
396.8M
Q1 2024
413.5M
Q2 2024
362.9M
Q3 2024
467.2M
Q4 2024
658.4M
Q1 2025
744.9M
Q2 2025
611.1M
Q3 2025
399.4M
Q4 2025
442.9M
Q1 2026
730.8M
Q2 2026
401.3M
2014
9.8M
2015
1.3M
2016
5.4M
2017
154.6M
2018
301.0M
2019
380.8M
2020
540.1M
2021
701.9M
2022
933.0M
2023
1.24B
2024
1.90B
2025
2.20B
→Revenue reached $2.2B in 2025, compounding +33% a year since 2022 though the pace has cooled. The last twelve months (-20%) ran below that pace, so growth is slowing. The trailing twelve months are already running at $2.0B, behind the last full year.
What this measures
The money customers paid, before any costs are taken out. Each bar is one quarter or, on the annual view, a full financial year; the last annual bar may be the trailing twelve months, which the footnote marks.
What good looks like. Growth that repeats, rather than one strong year carrying the chart, and a trailing twelve months keeping pace with the last full year.
If it rises or falls. Revenue is the hardest line to flatter, so a rise is the most trustworthy kind of growth. A fall puts pressure on every margin below it, because costs rarely come down as quickly as sales do.
Profit history
Is SRPT's net profit growing?
◌ dashed quarter = Q4 derived from the annual filing minus Q1, Q2 and Q3 (the SEC never receives a Q4 report)
Period
Net income ($)
Q3 2011
-4.0M
Q4 2011
-1.4M
Q1 2012
-17.7M
Q2 2012
8.0M
Q3 2012
-49.6M
Q4 2012
-62.1M
Q1 2013
-42.1M
Q2 2013
-19.1M
Q3 2013
-42.0M
Q4 2013
-8.8M
Q1 2014
-28.3M
Q2 2014
-33.9M
Q3 2014
-29.2M
Q4 2014
-44.4M
Q1 2015
-61.6M
Q2 2015
-41.9M
Q3 2015
-51.9M
Q4 2015
-64.7M
Q1 2016
-59.8M
Q2 2016
-62.3M
Q3 2016
-56.7M
Q4 2016
-88.5M
Q1 2017
84.1M
Q2 2017
-63.0M
Q3 2017
-47.7M
Q4 2017
-24.0M
Q1 2018
-35.4M
Q2 2018
-109.3M
Q3 2018
-76.4M
Q4 2018
-140.9M
Q1 2019
-76.6M
Q2 2019
-276.4M
Q3 2019
-126.3M
Q4 2019
-235.7M
Q1 2020
-17.5M
Q2 2020
-150.8M
Q3 2020
-196.5M
Q4 2020
-189.3M
Q1 2021
-167.3M
Q2 2021
-81.4M
Q3 2021
-48.1M
Q4 2021
-122.0M
Q1 2022
-105.0M
Q2 2022
-231.5M
Q3 2022
-257.7M
Q4 2022
-109.2M
Q1 2023
-516.8M
Q2 2023
-23.9M
Q3 2023
-40.9M
Q4 2023
45.7M
Q1 2024
36.1M
Q2 2024
6.5M
Q3 2024
33.6M
Q4 2024
159.0M
Q1 2025
-447.5M
Q2 2025
196.9M
Q3 2025
-50.6M
Q4 2025
-412.2M
Q1 2026
331.0M
Q2 2026
-4.9M
2011
-2.3M
2012
-121.3M
2013
-112.0M
2014
-135.8M
2015
-220.0M
2016
-267.3M
2017
-50.7M
2018
-361.9M
2019
-715.1M
2020
-554.1M
2021
-418.8M
2022
-703.5M
2023
-536.0M
2024
235.2M
2025
-713.4M
→2025 closed with a loss of $713M after being profitable the year before. One bad year is not a pattern, but it is what the balance sheet has to absorb.
What this measures
What is left after every cost, including tax and interest. The bottom line of the income statement.
What good looks like. Profit growing at least as fast as revenue, which means the business is keeping more of each sale as it gets bigger.
If it rises or falls. Profit can move for reasons revenue cannot explain - a one-off charge, a tax change, a write-down - so a single sharp year is worth checking against the margin chart before reading it as a trend.
Growth rate
How fast are SRPT's revenue and earnings growing?
Shown separately because they would flatten the axis: 2025 earnings -403% - rebounds off a collapsed prior year.
Year
Revenue growth
Earnings growth
2,015
-0.8716
-
2,016
3.3264
-
2,017
27.5158
-
2,018
0.9474
-
2,019
0.2651
-
2,020
0.4182
-
2,021
0.2996
-
2,022
0.3293
-
2,023
0.3326
-
2,024
0.5297
-
2,025
0.1558
-
2026
-0.2044
-
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year · on the quarterly views, growth is the trailing twelve months against the twelve before, or a quarter against the same quarter a year earlier
→Revenue fell 20% over the twelve months to 2026-06-30, against an average of +33% a year over 2021-2025.
What this measures
How much revenue and earnings changed against the year before - the trailing twelve months against the twelve before them at each quarter, or one point per fiscal year. It is the speed of the business, not its size.
What good looks like. The earnings line above the revenue line: profits growing faster than sales means each new dollar of sales arrives more profitably than the last.
If it rises or falls. A high growth rate off a small base is easy and gets harder every year, so slowing growth in a large business is normal rather than a warning. Earnings falling while revenue grows is the combination worth understanding: costs are rising faster than sales.
Per-share growth
Are SRPT's revenue and free cash flow per share growing?
Year
Revenue per share ($)
Free cash flow per share ($)
2,017
2.6282
-4.1483
2,018
4.5439
-6.7897
2,019
5.1733
-7.0107
2,020
6.9283
0.3241
2,021
8.6373
-5.9273
2,022
10.6558
-4.0678
2,023
13.4563
-6.2458
2,024
17.6313
-3.1772
2,025
21.956
-3.0708
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year · each quarterly point is the trailing twelve months to that quarter end, so the last one is the current figure
→Revenue per share reached $21.96 in 2025, compounding +27% a year against +33% for SRPT as a whole. Dilution absorbed about 5.8 points of that growth. The trailing twelve months are running at $19.72 a share. Free cash flow per share stands at $-3.07.
What this measures
Revenue and free cash flow, each divided by the number of shares in issue and adjusted for splits so old and new years compare honestly. Both lines rising means each share owns more of the business's sales and cash.
What good looks like. Both lines rising, and revenue per share growing at least as fast as the company's total revenue, which the answer compares. Faster means buybacks are working for you; slower means new shares are absorbing part of the growth.
If it rises or falls. This is the line that actually reaches you. A company can grow revenue every year and still shrink your slice by issuing shares faster than it grows.
What does “Growth” actually mean?
Growth here is what the company has actually reported to the SEC - not a forecast. We look at the last year, the three-year pace, whether growth is speeding up or slowing down, and whether it's been consistent rather than one lucky year. Hatched bars are fourth quarters we derived from annual filings (companies file a full-year 10-K rather than a Q4 report).
Profitability is thin or negative. The growth isn't turning into money yet.
-kept after direct costs
-7.3%kept after running costs
-9.9%profit on shareholders' money
-5.3%against a 10% cost of capital
-operating cash ÷ net income
Margins
What profit margin does SRPT keep on each sale?
Year
Gross
Operating
Net
2,014
-
-13.7121
-13.9171
2,015
-
-175.7255
-175.6026
2,016
-
-49.2031
-49.3018
2,017
-
-1.1103
-0.3279
2,018
-
-1.1415
-1.2022
2,019
-
-1.8527
-1.8777
2,020
-
-1.0446
-1.026
2,021
-
-0.655
-0.5966
2,022
-
-0.5747
-0.754
2,023
-
-0.2154
-0.4311
2,024
-
0.1147
0.1237
2,025
-
-0.3183
-0.3245
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year · each quarterly point is the trailing twelve months to that quarter end, so the last one is the current figure
→Operating margin widened 26 points to -32% since 2022. The bottom line is still negative: costs below the operating line eat what is left. SRPT doesn't tag a gross-profit line in its filings, so the chart starts at operating margin.
What this measures
What survives at three points on the way down the income statement: after the direct cost of the product, after the cost of running the company, and after everything.
What good looks like. Margins that hold or widen as the business grows. The level itself varies enormously by industry, so the shape over time tells you more than the number.
If it rises or falls. A widening margin means pricing power or costs under control. A compressing one means the opposite, and it compounds: on large revenue, two points of margin is a great deal of profit.
Earnings quality
Does SRPT's operating cash flow keep up with its profit?
Year
Cash from operations
Net income
2,011
-23.7M
-2.3M
2,012
-29.7M
-121.3M
2,013
-64.7M
-112.0M
2,014
-128.5M
-135.8M
2,015
-149.5M
-220.0M
2,016
-245.8M
-267.3M
2,017
-232.0M
-50.7M
2,018
-388.7M
-361.9M
2,019
-456.5M
-715.1M
2,020
107.5M
-554.1M
2,021
-443.2M
-418.8M
2,022
-325.3M
-703.5M
2,023
-501.0M
-536.0M
2,024
-205.8M
235.2M
2,025
-205.5M
-713.4M
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year · each quarterly point is the trailing twelve months to that quarter end, so the last one is the current figure
→The company generated -$205M of operating cash in 2025. With no profit to compare against, cash generation is the number that matters here.
What this measures
Reported profit against the cash the business actually collected from operating. Profit is an accounting judgement; cash is not.
What good looks like. Cash at or above profit, year after year. Depreciation and other non-cash charges usually push cash above profit, so roughly 100% or more is healthy.
If it rises or falls. Cash falling behind profit for more than a year is the classic early warning: the sales are booked but the money has not arrived, and it shows up in receivables and inventory. For a lender the comparison behaves differently, because a growing loan book consumes cash.
Returns on capital
What return on equity and on capital does SRPT earn?
Year
ROE
ROA
ROCE
2,012
-1.5681
-0.5917
-0.2355
2,013
-0.6039
-0.3841
-0.3532
2,014
-0.5488
-0.4603
-0.5182
2,015
-1.0047
-0.8037
-1.0411
2,016
-1.0142
-0.6302
-0.765
2,017
-0.09
-0.0388
-0.1407
2,018
-0.3974
-0.2204
-0.234
2,019
-0.7729
-0.3923
-0.4528
2,020
-0.7015
-0.1857
-0.2196
2,021
-0.4957
-0.133
-0.1706
2,022
-1.0716
-0.2249
-0.2137
2,023
-0.8615
-0.1642
-0.1026
2,024
0.1971
0.0594
0.0675
2,025
-0.5347
-0.213
-0.3104
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year · each quarterly point is the trailing twelve months to that quarter end, so the last one is the current figure
→ROE of -10% and ROCE of -5% sit close together, so the returns come from the business itself rather than from borrowing.
What this measures
Two returns side by side: on shareholders' capital (ROE), and on all the capital in the business including debt (ROCE).
What good looks like. Both comfortably above roughly 10%, and close together. A wide gap means borrowing, not operations, is doing the work.
If it rises or falls. A high ROE built on debt looks like quality until the debt has to be refinanced. ROCE is the harder number to flatter, which is why both are shown.
Cash conversion
How much of each sale does SRPT turn into free cash flow?
Period
FCF margin
2014
-15.7818
2015
-122
2016
-46.3311
2017
-1.5784
2018
-1.4942
2019
-1.3552
2020
0.0468
2021
-0.6862
2022
-0.3817
2023
-0.4642
2024
-0.1802
2025
-0.1399
→Free cash flow is negative, so no share of revenue is currently converting to spare cash. Every sales dollar is being reinvested or consumed.
What this measures
Free cash flow as a share of revenue: how much of each dollar of sales survives both costs and capital spending.
What good looks like. A steady or rising share. Asset-light businesses convert far more than manufacturers, so compare a company with itself.
If it rises or falls. Falling conversion while revenue grows means growth is being bought with capital spending or working capital, which is fine while it lasts and painful when it stops.
Spending intensity
How much of its revenue does SRPT spend on capex, R&D and stock pay?
Year
Capex % of rev
R&D % of rev
Stock comp % of rev
2,014
2.6078
9.6578
2.0852
2,015
2.7143
116.8348
25.6321
2,016
0.9852
34.7301
5.527
2,017
0.0776
1.0784
0.1971
2,018
0.2032
1.3349
0.1665
2,019
0.1566
-
0.2064
2,020
0.1522
-
0.2001
2,021
0.0548
-
0.1623
2,022
0.033
-
0.2497
2,023
0.0612
-
0.1468
2,024
0.072
-
0.0969
2,025
0.0464
-
0.0561
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year · each quarterly point is the trailing twelve months to that quarter end, so the last one is the current figure
→The biggest claim on each sales dollar is research and development, at 133% of revenue (stock compensation 6%, capital spending 5%). That share has fallen since 2015, so the cost of competing is easing.
What this measures
Capital spending, research and development, and stock compensation, each as a share of revenue. The three ways a business pays to keep its position.
What good looks like. A share that is stable or falling while revenue grows, which means the cost of competing is not rising with the business.
If it rises or falls. Rising intensity means each new dollar of sales is getting more expensive to win. Falling intensity can mean efficiency, or it can mean under-investment that shows up years later.
Return on capital employed
Is SRPT's return on capital above what its capital costs?
Period
Return on capital employed
2011
-1.064
2012
-0.2355
2013
-0.3532
2014
-0.5182
2015
-1.0411
2016
-0.765
2017
-0.1407
2018
-0.234
2019
-0.4528
2020
-0.2196
2021
-0.1706
2022
-0.2137
2023
-0.1026
2024
0.0675
2025
-0.3104
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year · each quarterly point is the trailing twelve months to that quarter end, so the last one is the current figure
→SRPT's return on capital is negative at -31.0% in 2025. The capital in the business is not yet earning anything back.
What this measures
The same return as the card above, but every filed year, against a 10% line that stands in for what capital costs.
What good looks like. Years above the line, and a trend that is flat or rising rather than drifting down towards it.
If it rises or falls. A business earning above its cost of capital creates value by growing; one earning below it destroys value by growing. The 10% line is a convention, not a law, so read the distance from it rather than the crossing.
What does “Quality” actually mean?
Quality asks whether the growth makes real money. Margins show how much of each sale survives costs; return on equity shows what shareholders earn on their capital; and the profit-to-cash comparison catches companies whose accounting profits never turn into actual cash.
TTM operating cash flow $111M on a net loss of $137M
IV
Financial health
●●●●●●4/6
Financially sound overall, with one or two things worth watching.
0.55xborrowed vs owned
4.4xnear-term bills coverage
2xearnings ÷ interest bill
$788Mcash plus short-term investments
Debt & cash
How much debt does SRPT carry, and do its profits cover the interest?
Year
Total debt
Cash & investments
2,012
1.8M
187.7M
2,013
1.7M
257.0M
2,014
1.6M
210.3M
2,015
29.3M
192.5M
2,016
27.8M
317.8M
2,017
437.2M
1.08B
2,018
430.1M
1.17B
2,019
681.9M
1.12B
2,020
992.5M
1.94B
2,021
563.7M
2.12B
2,022
1.54B
1.99B
2,023
1.34B
1.68B
2,024
1.14B
1.35B
2,025
829.0M
939.6M
2,026
847.6M
788.5M
◌ each quarterly point is the balance sheet at that quarter end
→Debt of $848M sits against $788M of cash, or 0.6x shareholders' equity. Earnings cover interest only 2.0 times, which is thin.
What this measures
Total borrowings against cash on hand, with debt as a multiple of shareholders' equity, and how many times profit covers the interest bill.
What good looks like. Interest covered comfortably - roughly eight times or more - and debt that is not a large multiple of equity.
If it rises or falls. Debt is only a problem when it has to be repaid or refinanced in a bad year, so cover matters more than the amount. Rising debt with rising cover is a business borrowing to grow; rising debt with falling cover is the combination that ends badly.
Near-term liquidity
Do SRPT's current assets cover the bills due within a year?
Period
Current ratio
2011
2.1933
2012
2.4581
2013
7.5295
2014
6.7213
2015
3.6046
2016
4.9518
2017
13.9094
2018
8.2111
2019
5.5479
2020
5.9737
2021
5.752
2022
4.1282
2023
3.946
2024
4.2005
2025
2.3171
◌ 2026 = the latest balance sheet (2026-06-30), not a fiscal year-end · each quarterly point is the balance sheet at that quarter end
→Near-term liquidity is comfortable: 4.4x of current assets for every dollar due within the year. That is stronger than in 2011.
What this measures
Current assets over current liabilities: what the company can turn into cash within a year against what it owes within a year.
What good looks like. Comfortably above 1.0, and not falling year after year. Below 1.0 means near-term bills exceed near-term resources, which is normal for some business models and a warning in others.
If it rises or falls. Inventory and receivables build it up; short-term borrowing and payables pull it down. A retailer that turns stock over quickly can run lower than a manufacturer and be perfectly sound.
Interest cover
How many times over can SRPT's operating profit pay its interest bill?
Period
Interest cover (x)
2011
-359.27
2012
-297.03
2013
-902.84
2014
-1,338
2015
-161.307
2016
-140.9778
2017
-29.5877
2018
-10.194
2019
-23.0057
2020
-9.411
2021
-7.2367
2022
10.0699
2023
12.1683
2024
-11.858
2025
18.3477
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year
→Operating profit covers the interest bill 2.0x over, which leaves little room. Cover is wider than in 2011.
What this measures
Operating profit divided by interest expense - how many times over the year's earnings could pay the year's interest.
What good looks like. High and steady. Five times is a common floor; comfortably above it means the debt is being carried, not merely serviced.
If it rises or falls. It falls when profit falls or when borrowing costs rise, and a company can look safe on the level while the direction is telling you otherwise.
Cash conversion
How much of SRPT's revenue arrives as operating cash?
Period
Operating cash flow / revenue
2014
-13.174
2015
-119.2857
2016
-45.3459
2017
-1.5008
2018
-1.2911
2019
-1.1986
2020
0.199
2021
-0.6314
2022
-0.3487
2023
-0.4029
2024
-0.1082
2025
-0.0935
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year · each quarterly point is the trailing twelve months to that quarter end, so the last one is the current figure
→5.6% of every dollar SRPT sold arrived as operating cash. Up from -1317.4% in 2014.
What this measures
Operating cash flow as a share of revenue: of every dollar sold, how much reached the bank before capital spending.
What good looks like. A high share, holding up or improving. It is the clearest sign that reported profit is real.
If it rises or falls. It falls when customers take longer to pay or stock builds up, and it can stay high while profit falls - which is usually the more reassuring of the two.
Shareholders' equity
Is SRPT's shareholder equity (book value) growing?
Period
Equity ($)
2012
123.7M
2013
247.2M
2014
247.7M
2015
190.3M
2016
336.7M
2017
789.2M
2018
1.03B
2019
818.2M
2020
761.8M
2021
928.0M
2022
384.9M
2023
859.3M
2024
1.53B
2025
1.14B
2026
1.53B
→The company's own capital grew from $859M in 2023 to $1.5B (+78%). The business is building book value rather than consuming it.
What this measures
What would be left for shareholders if every asset were sold at its book value and every debt repaid. Book value, in other words.
What good looks like. Equity growing as retained profits build up, unless the company is deliberately returning more than it earns.
If it rises or falls. Equity falls for two very different reasons: buybacks, which return money to you, and losses, which do not. The distinction is the whole story, and negative equity means liabilities now exceed assets, which makes debt-to-equity and return on equity meaningless rather than alarming.
What does “Health” actually mean?
Health asks one question: can the business survive a bad year? We check whether near-term bills are covered, whether debt is modest and shrinking, whether earnings comfortably pay the interest, and - for loss-makers - how many years of cash are left at the current burn rate.
What comes back to shareholders is thin or stretched. Read the checks before counting on it.
+1.38%bought back, TTM, over market value
-at the current rate
$25Mdividends plus buybacks
$99Mlast 12m, dilutes the buybacks
+599.7%since 2009 (split-adjusted)
Capital returned vs stock comp
Do SRPT's buybacks and dividends outweigh the stock it issues to staff?
Year
Buybacks
Dividends
Stock comp
2,023
-
-
182.5M
2,024
-
-
184.3M
2,025
25.0M
-
123.4M
→Shareholders received $25M in buybacks in 2025. Stock compensation issued $123M of new shares in the same year, offsetting 100% of that.
What this measures
Cash returned through buybacks and dividends, alongside the value of new shares issued to employees as compensation.
What good looks like. Returns comfortably larger than stock compensation, so the share count actually falls.
If it rises or falls. A company can announce billions in buybacks while issuing nearly as much stock to staff, and the two largely cancel. What reaches you is the net effect, which is why both bars are here rather than only the buyback.
Shareholder yield
What is SRPT's shareholder yield from dividends and buybacks?
Year
Buyback yield
Dividend yield
2,023
0
-
2,024
0
-
2,025
0.0055
-
◌ 2026 = at the latest close (2026-10-16), over the trailing twelve months; earlier years are annual averages
→SRPT handed back 1.4% of its market value over the last twelve months, below the 2% this check asks for. All of it is buybacks; SRPT pays no dividend.
What this measures
Dividends and buybacks, each as a percentage of what the company was worth that year. The dollar chart says how much came back; this says how much came back for the price.
What good looks like. A total that clears a couple of percent and holds. Which half it comes from matters less than whether it is sustained.
If it rises or falls. A yield rises when the price falls as readily as when the payout grows, so read a jump beside the price chart before treating it as generosity.
Share count change (split-adjusted)
Is SRPT's share count rising or falling?
Year
Share-count change
2,010
0.1949
2,011
0.1651
2,017
1.7232
2,018
0.1264
2,019
0.1112
2,020
0.059
2,021
0.0424
2,022
0.0775
2,023
0.0553
2,024
0.1675
2,025
-0.0719
→The share count shrank 7.2% in 2025. Buybacks are concentrating your ownership: the same business, split fewer ways.
What this measures
The yearly change in the number of shares in issue, adjusted for splits so the years compare. A bar below zero is a falling share count, usually from buybacks; above zero, new shares were issued.
What good looks like. A flat or falling share count. Falling means each share you hold owns a little more of the business every year.
If it rises or falls. A rising count divides the same business among more owners, so your slice shrinks unless profits grow faster. This is the most direct chart on the page: it is your ownership, measured.
Dilution against what it bought
Has SRPT's revenue per share grown faster than its share count?
Change since 2017. The gap between the lines is what each share gained or lost. Share counts are split-adjusted weighted averages.
Year
Share count, change since 2017
Revenue per share, change since 2017
2,017
0
0
2,018
0.1264
0.7289
2,019
0.2516
0.9684
2,020
0.3254
1.6361
2,021
0.3816
2.2864
2,022
0.4886
3.0545
2,023
0.5709
4.12
2,024
0.834
5.7086
2,025
0.7022
7.3541
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year · on the quarterly view, revenue per share is the trailing twelve months over that quarter's diluted count
→SRPT issued 545% more shares from 2009 to 2025, but revenue per share still rose 735%. The dilution bought more growth than it cost existing holders.
What this measures
The share count and revenue per share over the same years, both indexed to 100 at the start, so the two lines can be compared directly.
What good looks like. The per-share line above the share-count line: whatever the company did with its shares, more business ended up behind each one.
If it rises or falls. Issuing shares is not automatically bad. It is bad when the money raised buys less growth than the dilution cost, which is exactly what the gap between these two lines shows.
Why compare buybacks with stock compensation?
A company can trumpet billions in buybacks while quietly issuing nearly as much stock to employees. What matters to you is the net effect: is the share count actually falling? If not, the 'return' is mostly recycling.
→SRPT is in a downtrend: the price is below the cloud where recent trading settled and that cloud is still falling. Both shorter readings point down as well, so nothing here disagrees with the downtrend.
How the trend above is worked out
The trend read is the daily Ichimoku picture, the same indicator drawn on the chart above. Five names, and what each one is: the TENKAN is the midpoint of the last 9 sessions' high and low, the fast line; the KIJUN is the same over 26 sessions, the slow one; the two SENKOU spans are midpoints drawn 26 sessions into the FUTURE, and the band between them is the KUMO cloud - because it is drawn forward, the support for the coming weeks is already fixed and a change of its direction can be seen coming; the CHIKOU is today's close compared with the close 26 sessions back. A trend confirms itself in that order and the checks follow it: price clears the cloud, holds above both lines, the Tenkan crosses above the Kijun, the cloud ahead turns up, and the Chikou stands higher than the price a month ago. Six of six therefore means all of that at once; a price sitting inside the cloud, or below its own lines, cannot get there. The last check is the one Ichimoku cannot answer - whether the S&P 500 did better over 12 months (252 sessions), measured on the SPY ETF with dividends included, on the same adjusted basis as the stock's own price. Our figures are the last close we hold, refreshed every trading night; the chart is live. None of this says anything about the business, and it is not advice.
Are SRPT's insiders buying or selling shares with their own money?
Month
Buys ($)
Sells ($)
2023-11
5.9M
0
2023-12
0
0
2024-01
0
0
2024-02
0
0
2024-03
0
3.0M
2024-04
0
0
2024-05
0
508,900
2024-06
0
8.2M
2024-07
0
0
2024-08
5.0M
822,100
2024-09
0
0
2024-10
0
0
2024-11
0
0
2024-12
0
1.5M
2025-01
0
0
2025-02
0
0
2025-03
0
248,203
2025-04
0
0
2025-05
0
0
2025-06
0
0
2025-07
0
0
2025-08
0
0
2025-09
0
0
2025-10
0
0
2025-11
0
0
2025-12
0
294,202
2026-01
0
0
2026-02
0
0
2026-03
0
123,208
2026-04
0
0
2026-05
0
0
2026-06
0
0
2026-07
0
0
2026-08
0
0
2026-09
0
0
2026-10
0
0
→Since November 2023, insiders bought $11M and sold $15M on the open market, a net sale of $4M. A further 165 transactions were grants, option exercises or tax withholding, which say nothing either way.
What this measures
Open-market buys and sells by the company's own officers and directors, from their Form 4 filings. Grants, option exercises and shares withheld for tax are excluded, because they are compensation rather than decisions.
What good looks like. Buying with their own money, which is the one insider action that is hard to explain away.
If it rises or falls. Selling is weak evidence: insiders sell to diversify, to buy houses, and on pre-scheduled plans set months ahead. Buying is stronger evidence, because there is only one reason to do it. The absence of any buying over a long stretch is itself worth noticing.
The record
Who did what, exactly?
Date
Insider
Role
Type
Shares
Price
Value
2026-09-04
Ryan Ho-Yan Wong
Chief Financial Officer
tax
13,272
$22.22
$294,904
2026-09-04
Ian Michael Estepan
Chief Operating Officer
tax
24,799
$22.22
$551,034
2026-09-04
Cristin Rothfuss
EVP, General Counsel
tax
22,025
$22.22
$489,396
2026-09-04
Louise Rodino-Klapac
President, R&D and Tech Ops
tax
21,423
$22.22
$476,019
2026-03-12
Stephen Mayo
Director
SELL
7,239
$17.02
$123,208
2026-03-11
Ian Michael Estepan
Chief Operating Officer
tax
1,097
$17.03
$18,682
2026-03-11
Ryan Ho-Yan Wong
Chief Financial Officer
tax
256
$17.03
$4,360
2026-03-11
Louise Rodino-Klapac
President, R&D and Tech Ops
tax
948
$17.03
$16,144
2026-03-11
Cristin Rothfuss
EVP, General Counsel
tax
974
$17.03
$16,587
2026-03-09
Ryan Ho-Yan Wong
Chief Financial Officer
tax
162
$16.95
$2,746
2026-03-09
Ryan Ho-Yan Wong
Chief Financial Officer
tax
113
$16.95
$1,915
2026-03-09
Cristin Rothfuss
EVP, General Counsel
tax
484
$16.95
$8,204
2026-03-09
Cristin Rothfuss
EVP, General Counsel
tax
346
$16.95
$5,865
2026-03-09
Louise Rodino-Klapac
President, R&D and Tech Ops
tax
504
$16.95
$8,543
2026-03-09
Louise Rodino-Klapac
President, R&D and Tech Ops
tax
895
$16.95
$15,170
2026-03-09
Ian Michael Estepan
Chief Operating Officer
tax
1,036
$16.95
$17,560
2026-03-09
Ian Michael Estepan
Chief Operating Officer
tax
583
$16.95
$9,882
2026-03-02
Cristin Rothfuss
EVP, General Counsel
tax
408
$16.20
$6,610
2026-03-02
Ryan Ho-Yan Wong
Chief Financial Officer
tax
450
$16.20
$7,290
2026-03-02
Ian Michael Estepan
Chief Operating Officer
tax
3,301
$16.20
$53,476
2026-03-02
Ian Michael Estepan
Chief Operating Officer
tax
875
$16.20
$14,175
2026-03-02
Louise Rodino-Klapac
President, R&D and Tech Ops
tax
3,718
$16.20
$60,232
2026-03-02
Louise Rodino-Klapac
President, R&D and Tech Ops
tax
767
$16.20
$12,425
2026-02-26
Ian Michael Estepan
Chief Operating Officer
exercise
2,069
$13.71
$28,366
2026-02-26
Ian Michael Estepan
Chief Operating Officer
exercise
5,381
$13.71
$73,774
2026-01-29
Claude Nicaise
Director
exercise
10,500
$13.71
$143,955
2026-01-29
Claude Nicaise
Director
tax
6,780
$21.23
$143,939
2026-01-27
M Kathleen Behrens
Director
exercise
10,500
$13.71
$143,955
2026-01-27
M Kathleen Behrens
Director
tax
6,494
$22.17
$143,972
2025-12-16
Ian Michael Estepan
Chief Operating Officer
SELL
13,187
$22.31
$294,202
2025-12-01
Ryan Ho-Yan Wong
Chief Financial Officer
tax
80
$20.96
$1,677
2025-12-01
Ryan Ho-Yan Wong
Chief Financial Officer
tax
78
$20.96
$1,635
2025-11-28
Cristin Rothfuss
EVP, General Counsel
tax
229
$21.12
$4,836
2025-11-17
Louise Rodino-Klapac
President, R&D and Tech Ops
tax
4,582
$18.42
$84,400
2025-07-31
Ryan Ho-Yan Wong
Chief Financial Officer
tax
327
$16.42
$5,369
2025-05-16
Richard Barry
Director
exercise
12,350
$32.63
$402,981
Why do the transaction types matter so much?
Most insider filings are not trades: stock grants, option exercises and tax withholding are how executives get paid, and gifts are estate planning. The signal lives in open-market transactions - a buy means an insider chose to spend their own cash on the stock. Sells are murkier: many are pre-scheduled 10b5-1 plans set months in advance. That's why the chart counts only open-market activity, and the table labels every row.
VIII
Ownership
informational
102.3%on Form 13F, 30 June 2026
6.2%officers, directors, founders
59.4%together
Top holders
Who owns Sarepta Therapeutics stock?
Fund managers filing Form 13F held 102.3% of the company's shares on 30 June 2026. The largest holder is BlackRock, Inc., with 18.0%. Insiders hold 6.2%.
#
Holder
Stake
Shares
Value
Change
1
BlackRock, Inc.Fund manager
17.98%
19.0M
$325M
+28.7%
2
State Street CorpFund manager
8.44%
8.9M
$152M
+34.8%
3
Vanguard Portfolio Management LLCFund manager
7.93%
8.4M
$143M
+26.2%
4
Two Sigma Investments, LPFund manager
4.35%
4.6M
$79M
+0.1%
5
Vanguard Capital Management LLCFund manager
4.35%
4.6M
$79M
+0.3%
6
First Trust Advisors LPFund manager
4.13%
4.4M
$75M
+5.6%
7
AQR Capital Management LLCFund manager
4.10%
4.3M
$74M
-32.8%
8
Richard BarryDirector · Form 4, 4 June 2026
3.06%
3.2M
$55M
-
9
Geode Capital Management, LLCFund manager
2.62%
2.8M
$47M
+39.4%
10
Erste Asset Management GmbHFund manager
2.43%
2.6M
$44M
-13.5%
11
Marshall Wace, LLPFund manager
2.09%
2.2M
$38M
+204.3%
12
Morgan StanleyFund manager
2.09%
2.2M
$38M
-15.2%
13
Aberdeen Group plcFund manager
2.08%
2.2M
$38M
-5.3%
14
Bank of America CorpFund manager
1.95%
2.1M
$35M
-4.2%
15
Goldman Sachs Group IncFund manager
1.93%
2.0M
$35M
+89.4%
16
D. E. Shaw & Co., L.P.Holds over 5% · Form 13G, 30 September 2025
1.90%
2.0M
$34M
-
17
UBS Group AGFund manager
1.54%
1.6M
$28M
-27.2%
18
Federated Hermes, Inc.Fund manager
1.51%
1.6M
$27M
-11.0%
19
Northern Trust CorpFund manager
1.15%
1.2M
$21M
+67.2%
20
Millennium Management LLCFund manager
1.13%
1.2M
$20M
-2.3%
The full list of top holders is free with an account
Source: SEC Form 13F filings for the quarter to 30 June 2026, Schedules 13D and 13G, and Form 4. Shares on today's basis, value at the latest price.
Where does this list come from?
Fund managers with more than $100 million in US stocks report their holdings every quarter on Form 13F, up to 45 days after the quarter ends, so the fund figures are as of the last quarter end. A fund family reports as one manager, and funds together can report more than 100%: shares lent to short sellers are bought again by other funds, and both report them. Anyone holding more than 5% of a class files a Schedule 13D or 13G, and officers and directors report what they hold on Form 4 after every trade, so those rows carry their own dates. Short positions are not reported anywhere. A stake is the holder's shares as a share of all the company's shares, with other share classes converted at their market value.